Breaking News
Get 40% Off 0
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For Free Copy Portfolio
Close

GSK plc DRC (GSK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow GSK plc DRC's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
44.29 +0.05    +0.11%
29/05 - Closed. Currency in USD ( Disclaimer )
Pre Market
44.10
-0.19
-0.43%
8:10:16 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,082,708
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 44.16 - 44.35
GSK plc DRC 44.29 +0.05 +0.11%

NYSE:GSK Financials

 
A brief overview of the NYSE:GSK financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of GlaxoSmithKline over time.

GSK plc reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was GBP 7,363 million compared to GBP 6,951 million a year ago. Net income was GBP 1,046 million compared to GBP 1,490 million a year ago. Basic earnings per share from continuing operations was GBP 0.257 compared to GBP 0.368 a year ago. Diluted earnings per share from continuing operations was GBP 0.254 compared to GBP 0.365 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GSK Income Statement

Gross margin TTM 72.67%
Operating margin TTM 28.39%
Net Profit margin TTM 14.59%
Return on Investment TTM 25.12%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 7363 8052 8147 7178
Gross Profit 5448 5237 5904 5279
Operating Income 2247 1639 2556 2051
Net Income 1046 350 1464 1624

GSK Balance Sheet

Quick Ratio MRQ 0.55
Current Ratio MRQ 0.87
LT Debt to Equity MRQ 109.51%
Total Debt to Equity MRQ 128.41%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 58511 59005 60862 59461
Total Liabilities 45282 46210 48243 47302
Total Equity 13229 12795 12619 12159

GSK Cash Flow Statement

Cash Flow/Share TTM 1.88
Revenue/Share TTM 7.52
Operating Cash Flow  4.83%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 958 3196 2212 1307
Cash From Investing Activities -149 268 -491 -964
Cash From Financing Activities -1060 -3592 -1762 31
Net Change in Cash -270 -162 -18 317
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GSK Comments

Write your thoughts about GSK plc DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Hineser
William Hineser Feb 28, 2024 2:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Most large international pharm companies are good long term investments.
William Hineser
William Hineser Feb 05, 2024 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Finally, some improvement, with reservations.
William Hineser
William Hineser Nov 14, 2023 10:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One of the few pharm companies not improving. Why?
Arth Dlg
Arth Dlg Apr 27, 2023 9:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RSV approval is a great announcement. I am buying :)
Jeff Chui
Jeff Chui Sep 15, 2022 9:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy here 31.2 Someone just bought 700k shares ($21million) pre market
daniel daniel
daniel daniel Sep 15, 2022 9:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes i entered at the same price, went against my rule of waiting the SPY to fall to the support level which would be around 365, i hope it was not a trick to get some new hodlers .... yet i feel relaxed because of the high dividend
peter pan
peter pan Aug 18, 2022 7:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GSK will fall to $25 level. Mark my words.
Jay Ow
Jay Ow Aug 18, 2022 7:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They all can do whatever after covid fraud. I do not want see any of these MED stocks at all for me and for many others they are just Murderers
Dan Dc
DanDc Aug 17, 2022 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought @ 34.36
Jaeyong Lee
Jaeyong Lee Aug 17, 2022 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought @33.07
Dan Dc
DanDc Aug 17, 2022 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i bought for long term , now the stimulus in Europe will pump this stock.
Patricio Garnica
Patricio Garnica Aug 11, 2022 1:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is It a good entry point?
Mo Ali
Av8er31 Aug 11, 2022 1:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Absolutely.
William Hineser
William Hineser Aug 11, 2022 10:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Glad I don't have many shares.
True Thao
True Thao Aug 11, 2022 10:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🤣🤣🤣
Jonathan Sanders
Jonathan Sanders Aug 03, 2022 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GSK recently struck a deal to purchase Sierra Oncology (SRRA) for a total of $1.9 billion to bolster its oncology offerings.... what we think about this acquisition
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email